133 related articles for article (PubMed ID: 34606680)
1. Feasibility of dose-dense cisplatin-based chemotherapy in Japanese children with high-risk hepatoblastoma: Analysis of the JPLT3-H pilot study.
Watanabe K; Mori M; Hishiki T; Yokoi A; Ida K; Yano M; Fujimura J; Nogami Y; Iehara T; Hoshino K; Inoue T; Tanaka Y; Miyazaki O; Takimoto T; Yoshimura K; Hiyama E
Pediatr Blood Cancer; 2022 Feb; 69(2):e29389. PubMed ID: 34606680
[TBL] [Abstract][Full Text] [Related]
2. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study.
Zsiros J; Brugieres L; Brock P; Roebuck D; Maibach R; Zimmermann A; Childs M; Pariente D; Laithier V; Otte JB; Branchereau S; Aronson D; Rangaswami A; Ronghe M; Casanova M; Sullivan M; Morland B; Czauderna P; Perilongo G;
Lancet Oncol; 2013 Aug; 14(9):834-42. PubMed ID: 23831416
[TBL] [Abstract][Full Text] [Related]
3. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial.
Katzenstein HM; Langham MR; Malogolowkin MH; Krailo MD; Towbin AJ; McCarville MB; Finegold MJ; Ranganathan S; Dunn S; McGahren ED; Tiao GM; O'Neill AF; Qayed M; Furman WL; Xia C; Rodriguez-Galindo C; Meyers RL
Lancet Oncol; 2019 May; 20(5):719-727. PubMed ID: 30975630
[TBL] [Abstract][Full Text] [Related]
4. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
Häberle B; Bode U; von Schweinitz D
Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study.
Zsíros J; Maibach R; Shafford E; Brugieres L; Brock P; Czauderna P; Roebuck D; Childs M; Zimmermann A; Laithier V; Otte JB; de Camargo B; MacKinlay G; Scopinaro M; Aronson D; Plaschkes J; Perilongo G
J Clin Oncol; 2010 May; 28(15):2584-90. PubMed ID: 20406943
[TBL] [Abstract][Full Text] [Related]
6. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration.
Meyers RL; Maibach R; Hiyama E; Häberle B; Krailo M; Rangaswami A; Aronson DC; Malogolowkin MH; Perilongo G; von Schweinitz D; Ansari M; Lopez-Terrada D; Tanaka Y; Alaggio R; Leuschner I; Hishiki T; Schmid I; Watanabe K; Yoshimura K; Feng Y; Rinaldi E; Saraceno D; Derosa M; Czauderna P
Lancet Oncol; 2017 Jan; 18(1):122-131. PubMed ID: 27884679
[TBL] [Abstract][Full Text] [Related]
7. Treatment outcomes and prognostic factors in children with hepatoblastoma using a risk-stratified approach.
Srinivasan S; Prasad M; Parambil BC; Shrimal A; Gollamudi VRM; Subramani V; Ramadwar M; Khanna N; Baheti AD; Gala K; Patil V; Laskar S; Qureshi S; Chinnaswamy G
Pediatr Blood Cancer; 2023 Jul; 70(7):e30302. PubMed ID: 37046413
[TBL] [Abstract][Full Text] [Related]
8. Carboplatin-epirubicin regimen for the treatment of hepatoblastoma.
Blouin P; Brugières L; Tabone MD; Leverger G; Rubie H; Branchereau S; De Kraker J
Pediatr Blood Cancer; 2004 Feb; 42(2):149-54. PubMed ID: 14752879
[TBL] [Abstract][Full Text] [Related]
9. Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT.
Hishiki T; Matsunaga T; Sasaki F; Yano M; Ida K; Horie H; Kondo S; Watanabe K; Oue T; Tajiri T; Kamimatsuse A; Ohnuma N; Hiyama E
Pediatr Surg Int; 2011 Jan; 27(1):1-8. PubMed ID: 20922397
[TBL] [Abstract][Full Text] [Related]
10. Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies.
Illiano M; Colinard M; Taque S; Mallon B; Larue C; Laithier V; Vérité-Goulard C; Sudour-Bonnange H; Faure-Conter C; Coze C; Aerts I; De Maricourt CD; Paillard C; Branchereau S; Brugières L; Fresneau B
Hepatol Int; 2022 Feb; 16(1):125-134. PubMed ID: 34506008
[TBL] [Abstract][Full Text] [Related]
11. Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: a report from the Childrens Cancer Study Group.
Ortega JA; Krailo MD; Haas JE; King DR; Ablin AR; Quinn JJ; Feusner J; Campbell JR; Lloyd DA; Cherlow J
J Clin Oncol; 1991 Dec; 9(12):2167-76. PubMed ID: 1720452
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcome and pattern of failure in hepatoblastoma treated with a consensus protocol in Hong Kong.
Liu APY; Ip JJK; Leung AWK; Luk CW; Li CH; Ho KKH; Lo R; Chan EKW; Chan ACY; Chung PHY; Chiang AKS
Pediatr Blood Cancer; 2019 Jan; 66(1):e27482. PubMed ID: 30270490
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin in combination with cisplatin, 5-flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group study.
Katzenstein HM; Malogolowkin MH; Krailo MD; Piao J; Towbin AJ; McCarville MB; Tiao GM; Dunn SP; Langham MR; McGahren ED; Finegold MJ; Ranganathan S; Weldon CB; Thompson PA; Trobaugh-Lotrario AD; O'Neill AF; Furman WL; Chung N; Randazzo J; Rodriguez-Galindo C; Meyers RL
Cancer; 2022 Mar; 128(5):1057-1065. PubMed ID: 34762296
[TBL] [Abstract][Full Text] [Related]
14. Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: the SIOPEL group experience.
De Ioris M; Brugieres L; Zimmermann A; Keeling J; Brock P; Maibach R; Pritchard J; Shafford L; Zsiros J; Czaudzerna P; Perilongo G
Eur J Cancer; 2008 Mar; 44(4):545-50. PubMed ID: 18166449
[TBL] [Abstract][Full Text] [Related]
15. Improved survival outcome for hepatoblastoma based on an optimal chemotherapeutic regimen--a report from the study group for pediatric solid malignant tumors in the Kyushu area.
Suita S; Tajiri T; Takamatsu H; Mizote H; Nagasaki A; Inomata Y; Hara T; Okamura J; Miyazaki S; Kawakami K; Eguchi H; Tsuneyoshi M;
J Pediatr Surg; 2004 Feb; 39(2):195-8; discussion 195-8. PubMed ID: 14966739
[TBL] [Abstract][Full Text] [Related]
16. Multidisciplinary management of hepatoblastoma in children: Experience from a developing country.
Shanmugam N; Scott JX; Kumar V; Vij M; Ramachandran P; Narasimhan G; Reddy MS; Kota V; Munirathnam D; Kelgeri C; Sundaram K; Rela M
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27781375
[TBL] [Abstract][Full Text] [Related]
17. Outcome of hepatoblastoma treated with the JPLT-1 (Japanese Study Group for Pediatric Liver Tumor) Protocol-1: A report from the Japanese Study Group for Pediatric Liver Tumor.
Sasaki F; Matsunaga T; Iwafuchi M; Hayashi Y; Ohkawa H; Ohira M; Okamatsu T; Sugito T; Tsuchida Y; Toyosaka A; Nagahara N; Nishihira H; Hata Y; Uchino J; Misugi K; Ohnuma N;
J Pediatr Surg; 2002 Jun; 37(6):851-6. PubMed ID: 12037748
[TBL] [Abstract][Full Text] [Related]
18. Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer.
Jary M; Ghiringhelli F; Jacquin M; Fein F; Nguyen T; Cleau D; Nerich V; El Gani M; Mathieu P; Valmary-Degano S; Arnould L; Lassabe C; Lamfichekh N; Fratté S; Paget-Bailly S; Bonnetain F; Borg C; Kim S
Cancer Chemother Pharmacol; 2014 Jul; 74(1):141-50. PubMed ID: 24824852
[TBL] [Abstract][Full Text] [Related]
19. Tumor rupture in hepatoblastoma: A high risk factor?
Pondrom M; Pariente D; Mallon B; Taque S; Branchereau S; Chardot C; Laithier V; Tabone MD; Lejeune J; Faure-Conter C; Saumet L; Vérité C; Aerts I; Brugières L; Fresneau B
Pediatr Blood Cancer; 2020 Sep; 67(9):e28549. PubMed ID: 32618436
[TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group.
Ortega JA; Douglass EC; Feusner JH; Reynolds M; Quinn JJ; Finegold MJ; Haas JE; King DR; Liu-Mares W; Sensel MG; Krailo MD
J Clin Oncol; 2000 Jul; 18(14):2665-75. PubMed ID: 10894865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
